GMDA

Gamida Cell Ltd
1.75
0.06 (3.55%)
1.75
Volume 6,558
Bid Price 1.70
Ask Price 1.75
News -
Day High

Low
1.10

52 Week Range

High
4.72

Day Low
Company Name Stock Ticker Symbol Market Type
Gamida Cell Ltd GMDA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 3.55% 1.75 08:10:21
Open Price Low Price High Price Close Price Prev Close
1.69
Trades Volume Avg Volume 52 Week Range
27 6,558 - 1.10 - 4.72
Last Trade Time Type Quantity Stock Price Currency
08:20:44 10 $ 1.7485 USD

Period:

Draw Mode:

Gamida Cell Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 130.52M 74.58M 64.64M $ - $ - -1.52 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 60.50k 1.20%

more financials information »

Gamida Cell News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GMDA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.631.74991.551.67415,8890.127.36%
1 Month1.461.74991.41011.59396,3700.2919.86%
3 Months1.901.901.101.45530,740-0.15-7.89%
6 Months2.213.661.102.02585,791-0.46-20.81%
1 Year3.244.721.102.35572,829-1.49-45.99%
3 Years4.7815.001.104.86528,959-3.03-63.39%
5 Years8.3015.411.104.92380,492-6.55-78.92%

Gamida Cell Description

Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.